BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) stock forecast from 0 analysts, the average analyst target price for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) is not available over the next 12 months. BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)’s stock price was CAD 0.46. BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)’s stock price has changed by +3.37% over the past week, -17.86% over the past month and +15.00% over the last year.
No recent analyst target price found for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)
No recent average analyst rating found for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)
Company Overview BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)
BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Read Less
BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceuti...Read More
Frequently Asked Questions About BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA) Stock
Stock Target Advisor's fundamental analysis for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s stock is Slightly Bearish.
Unfortunately we do not have enough data on BNXT:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNXT:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BNXT:CA's stock to indicate if its overvalued.
The last closing price of BNXT:CA's stock was CAD 0.46.
The most recent market capitalization for BNXT:CA is CAD 0.06B.
Unfortunately we do not have enough analyst data on BNXT:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s stock.
As per our most recent records BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) has 0 Employees.
BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s registered address is 1820 Fir Street, Vancouver, BC, Canada, V6J 3B1.
You can get more information about it from BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s website at https://www.bionxt.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) (BNXT:CA) Stock
Stock Target Advisor's fundamental analysis for BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s stock is Slightly Bearish.
Unfortunately we do not have enough data on BNXT:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNXT:CA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BNXT:CA's stock to indicate if its overvalued.
The last closing price of BNXT:CA's stock was CAD 0.46.
The most recent market capitalization for BNXT:CA is CAD 0.06B.
Unfortunately we do not have enough analyst data on BNXT:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s stock.
As per our most recent records BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11) has 0 Employees.
BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s registered address is 1820 Fir Street, Vancouver, BC, Canada, V6J 3B1.
You can get more information about it from BioNxt Solutions Inc. (formerly was XPHY/XPhyto Therapeutics Corp. until 2022-11-11)'s website at https://www.bionxt.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BNXT:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
